Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield KS Prior Auth Policy Update…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Modifiedblue cross blue shield - kansasPolicy N/A

    Medical Pharmacy Implementation Prior Authorization Program (BCBSKS)

    Customize your policy alerts

    Sign up for all blue cross blue shield - kansas policy alerts

    Know when blue cross blue shield - kansas releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Notifies providers that Blue Cross and Blue Shield of Kansas is transitioning management of certain medical-benefit specialty drugs to Prime Therapeutics' Medical Pharmacy Solutions (MPS) team, effective August 15, 2025, and describes prior authorization (PA) submission workflows, impacted places of service, in-scope HCPCS/J-codes and provider responsibilities.

    Policy Summary
    Payerblue cross blue shield - kansas
    PolicyMedical Pharmacy Implementation Prior Authorization Program (BCBSKS)
    Policy CodePolicy N/A
    Change TypeVendor transitionPA workflow change
    Effective DateAug 15, 2025
    Next Review Date
    Key ActionObtain prior authorization from Prime Therapeutics Medical Pharmacy Solutions via GatewayPA.com (routine) or 800-424-1713 (urgent/retro) for services on/after 2025-08-15; providers may contact Prime beginning 2025-08-07.
    SourceLink
    POLICY UPDATE CHANGES

    Responsibility for prior authorization reviews for the listed medical-benefit specialty drugs is transitioned to Prime Therapeutics Medical Pharmacy Solutions, effective 2025-08-15.

    PA submission workflow changed for providers previously using Prime MDR or Prime Therapeutics Pharmacy Benefit Team via CoverMyMeds/fax.

    ManyIn-scope drug HCPCS/J-codes listed
    2025-08-15Program effective date
    Commercial/ExchangeImpacted member plans

    What is changing

    Blue Cross and Blue Shield of Kansas (BCBSKS) is transitioning responsibility for prior authorization (PA) reviews of many specialty, practitioner-administered medical-benefit drugs to Prime Therapeutics' Medical Pharmacy Solutions (Prime). The program applies to the practitioner-administered drugs listed in the bulletin and requires PA when administered in the listed places of service for impacted members.

    The change applies to Commercial/Exchange member plans and is effective for dates of service on or after 2025-08-15. Providers may begin contacting Prime on 2025-08-07 to obtain prior authorizations for treatments with dates of service on or after 2025-08-15.

    Beginning with the effective date, providers must submit PA requests for in-scope medical-benefit drugs to Prime's Medical Pharmacy Solutions team (routine requests via GatewayPA.com; urgent/retroactive requests by phone at 800-424-1713). Providers who previously used the Prime Therapeutics Pharmacy Benefit Team via CoverMyMeds or fax will need to change their PA submission workflow to Prime's MPS processes.

    Key facts
    Program vendorPrime Therapeutics Medical Pharmacy Solutions (MPS)
    PA effective date2025-08-15
    Provider contact start
    Policy Summary
    Payerblue cross blue shield - kansas
    PolicyMedical Pharmacy Implementation Prior Authorization Program (BCBSKS)
    Policy CodePolicy N/A
    Change TypeVendor transitionPA workflow change
    Effective DateAug 15, 2025
    Next Review Date
    Key ActionObtain prior authorization from Prime Therapeutics Medical Pharmacy Solutions via GatewayPA.com (routine) or 800-424-1713 (urgent/retro) for services on/after 2025-08-15; providers may contact Prime beginning 2025-08-07.
    SourceLink
    On This Page
    What is changingIn-scope HCPCS / J-codes requiring prior authorizationPrior authorization requirement (criteria)Actions required of providersFAQs & contact instructionsDefinitionsDocument changes
    2025-08-07
    Impacted plansCommercial/Exchange
    Places of servicePractitioner-administered POS (see provider actions for requirements)

    In-scope HCPCS / J-codes requiring prior authorization

    In-scope HCPCS / J-codes (requires PA under program)HCPCS|CPT|mixedCovered
    Q2055Abecma / bendamustine (Baxter) / Elaprase (various brand associations listed)
    J9264Abraxane / Bendeka / Elelyso / Glassia / associated J-codes noted
    J3262Actemra IV / BeneFIX / Elfabrio / Granix / associated J-codes noted
    J0801Acthar_HP / Benlysta IV / Eloctate / Haegarda / associated J-codes noted
    J0599Miscellaneous drug code referenced
    J0791Adakveo / Beovu / Elrexfio / Halaven / associated J-codes noted
    J9042Adcetris / Berinert / Elzonris / Hemlibra / associated J-codes noted
    J9029Adstiladrin / Bkemv / Empaveli / Hemofil M / associated J-codes noted
    J7192Advate / Blincyto / Enhertu / Herceptin / associated J-codes noted
    J7207Adynovate / Breyanzi / Enjaymo / Herceptin Hylecta / associated J-codes noted
    1–10 of 71
    1/8

    Prior authorization requirement (criteria)

    Prior Authorization Requirement for In-Scope Medical-Benefit Drugs

    Prior authorization is required by Prime when the drugs are administered by practitioners in the listed places of service and for listed member plans for dates of service on or after August 15, 2025.

    Prior Authorization Requirement

    • Drug in scope: Drug is listed among the in-scope HCPCS/J-codes enumerated in this bulletin (see code_groups).
    • Place of service is one of the practitioner-administered POS requiring PA as referenced in the bulletin.

      Specific POS codes are referenced in the bulletin's 'Places of Service' section.

    • Impacted member plan: Member is enrolled in an impacted plan (Commercial/Exchange Members).
    • Date of service is on or after 2025-08-15. Providers may begin contacting Prime on 2025-08-07 for treatments with dates of service on/after 2025-08-15.

    Actions required of providers

    Prior Authorization

    New prior authorization vendor and effective date

    Beginning August 15, 2025, Prime Therapeutics Medical Pharmacy Solutions will perform prior authorization reviews for the listed medical-benefit drugs; providers must obtain PA from Prime for services on/after this date. Providers may begin contacting Prime on August 7, 2025 for treatments starting on or after August 15, 2025.

    • Contact Prime beginning 2025-08-07 for treatments on/after 2025-08-15
    • Effective date: 2025-08-15
    Prior Authorization

    How to submit PA requests

    Providers must submit PA requests for in-scope medical-benefit drugs to Prime via GatewayPA.com for routine requests. Urgent, expedited, or retroactive requests must be phoned to Prime at 800-424-1713. Providers previously using CoverMyMeds and/or fax to request medical-benefit drug reviews must change workflows and begin submitting reviews to Prime's Medical Pharmacy Solutions team.

    • Routine requests: GatewayPA.com (portal for routine requests)
    • Urgent/retroactive/expedited requests: call Prime Operations at 800-424-1713 (Prime has staff available 24/7 for urgent requests)
    • This replaces prior CoverMyMeds/fax workflows for medical-benefit drug reviews
    Documentation Required

    Required information for PA requests

    PA requests must include provider, member, medication, and clinical information as detailed below. Include complete ordering and rendering provider details, member demographics, medication administration details (including place of service and HCPCS/drug), dosing and timing, and supporting clinical documentation.

    • Ordering/rendering provider: name, Tax ID (TIN), practice address, office telephone and fax
    • Member demographics: member name, date of birth, member ID number, height, weight, diagnosis code
    • Medication details: place of service code, requested drug name or HCPCS code, dosage, frequency, anticipated start date of treatment
    • Clinical documentation examples: clinical notes, pathology reports, relevant test results
    Billing Rule

    Transition of care and authorization continuity

    Authorizations issued by BCBSKS for dates of service before August 15, 2025 remain effective until their stated end date. To continue treatment after an authorization expires, providers must obtain a new authorization from Prime prior to the authorization end date. Claims for dates of service after the authorized end date will be denied if a successive authorization from Prime has not been obtained.

    • Operational note: claims for dates after the authorized end date will be denied if successive authorization from Prime is not obtained prior to expiration
    Documentation Required

    Prime review escalation process

    If additional detail is needed during review, the case will be routed to a Prime pharmacist for provider outreach. Cases may be escalated to a Prime physician who will discuss the case with the ordering provider.

    • Escalation path: Prime pharmacist outreach, then Prime physician escalation if needed

    FAQs & contact instructions

    Q: When can providers begin contacting Prime for PA?

    A: Providers may begin contacting Prime on August 7, 2025 for treatments with dates of service on or after August 15, 2025.

    Q: How are urgent or retrospective PA requests handled?

    A: Urgent and retroactive requests must be phoned to Prime Operations at 800-424-1713; Prime has staff available 24/7 for urgent requests by phone.

    Quick contacts
    PortalGatewayPA.com
    Phone for urgent/retro requests800-424-1713
    VendorPrime Therapeutics Medical Pharmacy Solutions (MPS)

    Definitions

    Prime: Prime Therapeutics — the Medical Pharmacy Solutions (MPS) team at Prime will administer the prior authorization program and perform reviews for the in-scope medical-benefit specialty drugs.

    GatewayPA.com: GatewayPA.com — Prime Therapeutics' online portal for submitting routine prior authorization requests (urgent/retroactive requests must be phoned to Prime).

    Document changes

    ChangeLatest

    Responsibility for prior authorization reviews for the listed medical-benefit specialty drugs is transitioned to Prime Therapeutics Medical Pharmacy Solutions, effective 2025-08-15.

    Change

    PA submission workflow changed for providers previously using Prime MDR or Prime Therapeutics Pharmacy Benefit Team via CoverMyMeds/fax.